SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?

Expert Opin Ther Pat · 2014-05-30

DOI: 10.1517/13543776.2014.915945PMID: 24875782

Check source for accessEditorialOriginal source ↗

Research overview

Source publication and reading guides

This section identifies the original publication. Follow the source for its authors and journal.

Read the original publication ↗

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.